Kamene Kimenye

6 та иш

Programmatic Management of Drug-Resistant Tuberculosis, Nairobi, Kenya

1. Revised Definitions of Multidrug-Resistant Tuberculosis Treatment Outcomes: Closer to the Reality?

   Mathieu Bastard, Maryline Bonnet, Philipp du Cros +9

   БошқаTuberculosis Research and EpidemiologyAmerican Journal of Respiratory and Critical Care Medicine20151 иқтибос

   ABIABI:AkademIndex/openalex/2015.other.000002

2. Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB)

   Maryline Bonnet, Mathieu Bastard, Philipp du Cros +7

   МақолаTuberculosis Research and EpidemiologyEuropean Respiratory Journal20130 иқтибос

   ABIABI:AkademIndex/openalex/2013.article.000365

3. A multicentric cohort analysis of culture conversion and reversion in multidrug resistant tuberculosis (MDRTB) patients

   Cathy Hewison, Teshome Ashagre, Tigay Zinaida +7

   МақолаTuberculosis Research and EpidemiologyEuropean Respiratory Journal20130 иқтибос

   ABIABI:AkademIndex/openalex/2013.article.000437

4. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study

   M. Bonnet, Mathieu Bastard, Philipp du Cros +9

   МақолаTuberculosis Research and EpidemiologyThe International Journal of Tuberculosis and Lung Disease20150 иқтибос

   ABIABI:AkademIndex/openalex/2015.article.000040

5. Reply: How Do the New Definitions for Multidrug-Resistant Tuberculosis Treatment Outcomes Really Perform?

   Mathieu Bastard, Maryline Bonnet, Philipp du Cros +9

   БошқаTuberculosis Research and EpidemiologyAmerican Journal of Respiratory and Critical Care Medicine20150 иқтибос

   ABIABI:AkademIndex/openalex/2015.other.000005

6. Outcomes of HIV-infected versus HIV-non-infected patients treated for drug-resistance tuberculosis: Multicenter cohort study

   Mathieu Bastard, Elisabeth Sánchez-Padilla, Philipp du Cros +12

   МақолаTuberculosis Research and EpidemiologyPLoS ONE20180 иқтибос

   ABIABI:AkademIndex/openalex/2018.article.000060